TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02933411

Intervention type: OTHER
Intervention: Genetic Analysis
Description: Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
Study: NCT02108171

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Study: NCT02909205

Intervention type: OTHER
Group type: OTHER
Intervention: sensitization / educational program
Description: the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy

Intervention type: OTHER
Group type: OTHER
Intervention: training / sensitization program
Description: diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
Study: NCT02933411

Intervention type: OTHER
Intervention: Medical Record Data Abstraction
Description: The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded.

Intervention type: OTHER
Intervention: Pictorial Blood Assessment Chart (PBAC) score
Description: PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.

Intervention type: OTHER
Intervention: Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Description: Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
Study: NCT02537275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea
Description: tinted contact lens, daily-wear tinted lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeLIKe Shine, Koryo Eyetech Co
Description: clear lens
Study: NCT01295632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
Study: NCT01295632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: 300 mg capsule, orally, 6 capsules per dose, once each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: 300 mg capsule, orally, 6 capsules per dose, once each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: 300 mg capsule, orally, 6 capsules per dose, once each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
Study: NCT01295632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
Study: NCT00112593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01295632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
Study: NCT02144389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel (PZQ)
Description: 40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (ARA)
Description: ARA (40% of total fatty acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PZQ+ARA
Description: A single dose of PZQ administered seven days in advance of initial treatment with ARA.
Study: NCT00643682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational card
Description: A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy.
Study: NCT02125812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scaling and systemic moxifloxacin
Description: scaling and root planing (SRP) combined with systemic moxifloxacin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing
Description: scaling and root planing
Study: NCT01279954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years.
Study: NCT04387591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling(FSN)
Description: In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (\>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction
Study: NCT04874649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon-blowing breathing
Description: Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
Study: NCT03128372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desaturation
Description: The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Study: NCT04296344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy Treatments
Description: 10 consecutive weekly group acupuncture therapy treatments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy Sessions
Description: 8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
Study: NCT03272009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Capsules administered orally. Number of morning and evening capsules depending on treatment arm
Study: NCT04874649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained maximal inspiration breathing
Description: Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
Study: NCT03272009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Capsules administered orally. Number of morning and evening capsules depending on treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral administration, identical in appearance to the EYP001a capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral administration, identical in appearance to the EYP001a capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alfa-2a
Description: Ready-to-Use pre-filled syringes for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alfa-2a
Description: Ready-to-Use pre-filled syringes for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peg-interferon alfa-2a
Description: Ready-to-Use pre-filled syringes for subcutaneous injection
Study: NCT00945685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endymion Imagine™ System for Skin Tightening
Description: Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);
Study: NCT03196206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension
Study: NCT00782756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radiotherapy (RT) in combination with temozolomide and bevacizumab
Description: Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly.
Study: NCT03515265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber reinforced resin composite restoration
Description: a type of resin composite with improved strength due to the fiber's action

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microhybrid resin composite restoration
Description: a type of conventional resin composite
Study: NCT03979495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mFOCUS
Description: To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mFOCUS
Description: To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
Study: NCT03421249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Muscle strengthening exercises of the hip and knee muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Muscle strengthening exercises of the hip and knee muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic field therapy
Description: Electromagnetic field therapy with Magnetron®
Study: NCT03979495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mFOCUS
Description: To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
Study: NCT00871468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior plate
Description: Open reduction internal fixation (ORIF) clavicle with superior plate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior-inferior plate
Description: ORIF clavicle with anterior inferior plate
Study: NCT03421249

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electromagnetic field therapy
Description: Electromagnetic field therapy with Magnetron®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic field therapy
Description: Electromagnetic field therapy with Magnetron®
Study: NCT04378894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.